PRESENTATION

Q4 2021 — Results presentation

Q4 2021PDF · 33 pages4.2 MB
1

-- 1 of 33 --

4th Quarter 2021
Earnings Call
January 25, 2022

-- 2 of 33 --

Cautionary Note on Forward-looking Statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, market position, business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these
forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the
COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical
procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors,
such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action,
including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in
behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the
health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely
basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health
Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual
Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in
the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website at www.investor.jnj.com.
3

-- 3 of 33 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic
partners or licensed from other companies. The following is an acknowledgement of those relationships:

-- 4 of 33 --

Enterprise Highlights
Sales Performance and Earnings Review
Capital Allocation and Guidance
CEO Remarks
Q&A
Agenda
1
2
3
4
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Joaquin Duato
Chief Executive Officer
5
5

-- 5 of 33 --

Regional Sales Results Q4 2021 Q4 2020
% CHANGE
Reported Operational1
U.S. $12.2 $11.8 3.0% 3.0%
Europe 6.9 5.3 31.4 34.7
Western Hemisphere
(ex U.S.) 1.5 1.4 3.9 5.0
Asia-Pacific, Africa 4.3 4.0 6.6 9.0
International 12.6 10.7 18.5 21.2
Worldwide (WW) $24.8 $22.5 10.4% 11.6%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
4th Quarter 2021 Sales
Dollars in Billions
6

-- 6 of 33 --

14.5%; 17.2%1
Q4 2021 Q4 2020
$2.13
$1.86
4th Quarter 2021 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational %1
7
Sales
Adjusted Earnings2 Adjusted EPS2
10.4%; 11.6%1
$24.8 $22.5
GAAP Earnings
172.5%
$4.7
$1.7
14.4%
Q4 2021 Q4 2020
GAAP EPS
172.3%
$1.77
$0.65
Q4 2021	Q4 2021 Q4 2020 Q4 2020	Q4 2021 Q4 2020
$5.7
$5.0
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 7 of 33 --

Regional Sales Results 2021 2020
% CHANGE
Reported Operational1
U.S. $47.2 $43.1 9.3% 9.3%
Europe 23.6 19.0 24.3 20.7
Western Hemisphere
(ex U.S.) 5.8 5.3 7.8 7.3
Asia-Pacific, Africa 17.3 15.1 14.1 11.4
International 46.6 39.5 18.2 15.3
Worldwide (WW) $93.8 $82.6 13.6% 12.2%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
Full Year 2021 Sales
Dollars in Billions
8

-- 8 of 33 --

22.0%; 20.2%1
2021 2020
$9.80
$8.03
Full Year 2021 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational %1
9
Sales
Adjusted Earnings2 Adjusted EPS2
13.6%; 12.2%1
$93.8
$82.6
GAAP Earnings
41.9%
$20.9
$14.7
22.2%
2021 2020
GAAP EPS
41.7%
$7.81
$5.51
2021	2021 2020 2020	2021 2020
$26.2
$21.4
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 9 of 33 --

OTC
$1,373 Skin Health/Beauty
$1,084
Oral Care
$405
Baby Care
$399
Women's Health
$233
Wound Care/Other
$164
$3,657
1.1%, 1.8%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Consumer Health Highlights – 4th Quarter 2021
Solid adjusted operational growth2 driven by OTC
10
Key Drivers of Operational Performance1
OTC
• Growth driven by increased U.S. adult and pediatric fever incidences (TYLENOL,
MOTRIN) and WW category recovery for Cough, Cold, & Flu and Digestive Health, as
well as U.S. share gains across multiple brands (TYLENOL, MOTRIN) partially offset by
lapping prior year additional shipping days
Skin
Health/
Beauty
• Decline driven by DR. CI LABO - Sedona divestiture in ASPAC, lapping prior year
additional shipping days, and U.S. external supply constraints partially offset by WW
COVID-19 recovery and e-commerce strength
Oral Care
• Decline driven by lapping prior year additional shipping days, floss divestiture and
category declines in EMEA partially offset by successful brand building and promotional
campaigns in ASPAC
Baby Care
• Decline driven by lapping prior year additional shipping days and retailer stocking,
coupled with U.S. external supply constraints partially offset by AVEENO Baby strength
primarily due to ASPAC e-commerce growth
Women’s
Health
• Growth driven by COVID-19 market recovery in LATAM partially offset by lapping prior
year additional shipping days
Wound
Care/Other
• Decline driven by lapping prior year additional shipping days and professional tape
divestiture, along with product discontinuations in ASPAC partially offset by U.S.
category growth and U.S. strength in BAND-AID® Brand Adhesive Bandages
Adjusted Operational Sales2: WW 2.9%, U.S. 1.9%, Int’l 3.6%
Additional 2020 shipping days negatively impacted WW growth by ~4%
Reported: WW 1.1%, U.S. 1.3%, Int’l 0.9%
Operational1: WW 1.8%, U.S. 1.3%, Int’l 2.1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
15.9%, 15.8%
(1.6)%, 1.3%
(6.2)%, (6.4)%
(2.0)%, (0.8)%
(7.6)%, (6.5)%
(8.0)%, (7.1)%

-- 10 of 33 --

Key Drivers of Operational Performance1
Immunology
• Growth driven by continued strong uptake of STELARA in Crohn’s Disease and
Ulcerative Colitis, partially offset by negative U.S. prior period rebate adjustment
and reserve adjustment
• Strength in TREMFYA in Psoriasis and uptake in Psoriatic Arthritis
• REMICADE decline due to biosimilar competition
Infectious
Diseases
• Growth driven by the contribution of the COVID-19 vaccine
• Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA
and PREZISTA OUS LOE
Neuroscience
• Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts
and persistency, as well as the launch of INVEGA HAFYERA
Oncology
• DARZALEX increase driven by continued strong market growth and share gains in
all regions and solid uptake of the subcutaneous formulation launched in 2020
• Continued strong global launch uptake of ERLEADA
• IMBRUVICA maintained its market leadership but declined worldwide due to
competitive pressures from novel oral agents. U.S. decline partially offset by
growth in all regions outside of the U.S.
Cardiovascular/
Metabolism/
Other
(CVM/Other)
• Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition
• INVOKANA/INVOKAMET decline due to continued share erosion
Pulmonary
Hypertension
(PH)
• Portfolio was roughly flat due to COVID-19 related market restraints and generic
entrants in Other Pulmonary Hypertension offset by U.S. share uptake in both
OPSUMIT and UPTRAVI
Adjusted Operational Sales2: WW 18.6%, U.S. 4.2%, Int’l 38.6%
Additional 2020 shipping days negatively impacted WW growth by ~4%
Immunology
$4,355
Infectious Diseases
$2,437
Neuroscience
$1,793
Oncology
$3,778
CVM/Other
$1,074
PH
$851	$14,288
16.5%, 17.9%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Pharmaceutical Highlights – 4th Quarter 2021
11
Reported: WW 16.5%, U.S. 4.2%, Int’l 33.4%
Operational1: WW 17.9%, U.S. 4.2%, Int’l 36.9%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
(14.3)%, (13.8)%
(1.6)%, (0.2)%
10.0%, 12.3%
5.5%, 7.1%
167.3%, 168.8%
6.1%, 7.1%
Continued above-market performance driven by Oncology, Immunology, and Neuroscience

-- 11 of 33 --

Orthopaedics
$2,155
Surgery
$2,513
Vision
$1,171
Interventional
Solutions
$1,019
$6,859
4.1%, 5.3%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Medical Devices Highlights – 4th Quarter 2021
Growth primarily driven by COVID-19 market recovery, commercial initiatives, and innovation
12
Reported: WW 4.1%, U.S. 1.0%, Int’l 7.0%
Operational1: WW 5.3%, U.S. 1.0%, Int’l 9.3%
Key Drivers of Operational Performance1
Interventional
Solutions
• Market recovery, success of new products (VIZIGO and CARTO V7) and commercial strategies
continuing to enhance global leadership
Orthopaedics
• Hips: Growth reflects market recovery combined with continued strength of our portfolio
including the ACTIS stem and enabling technologies – KINCISE and VELYS Hip Navigation
• Trauma: Growth reflects global market recovery and uptake of new products including
Cannulated Compression Headless Screws, Advanced Nailing Systems and FIBULINK
• Knees: Flat reflecting variability in regional procedure recovery due to COVID-19, channel mix
and the positive impact of new products
• Spine, Sports & Other: Decline driven primarily by COVID-19 related impacts on the market
partially offset by new products (X-PAC, CONDUIT and SYMPHONY) and inventory fluctuations
in ASPAC
• Spine: WW: ~(9%), U.S.: ~(15%), OUS Flat
Surgery
• Advanced:
• Endocutters: ~+2% Driven by market recovery, new products (ECHELON Staple Line
Reinforcement) and market expansion offsetting competitive pressure in the U.S.
• Biosurgery: ~+10% Market recovery and share momentum driven by success of newer
products (VISTASEAL and SURGICEL POWDER) and ASPAC market expansion
• Energy: ~+10% Primarily due to market recovery, new products (ENSEAL X1) and market
expansion offsetting competitive pressures in the U.S.
• General: Growth primarily driven by market recovery and continued strength of the Suture
portfolio
Vision
• Contact Lenses/Other: Growth driven primarily by market recovery, new products (ACUVUE
OASYS Multifocal and ACUVUE DEFINE Fresh) and stocking fluctuations in the U.S.
• Surgical: Growth primarily due to market recovery and market share momentum driven by
uptake of recently launched products (TECNIS EYHANCE and TECNIS SYNERGY)
Adjusted Operational Sales2: WW 5.6%, U.S. 1.2%, Int’l 9.8%
Additional 2020 shipping days negatively impacted WW growth by ~4%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding; Beginning in the fiscal first quarter of 2022, the Medical Devices segment will be referred to as the MedTech segment
14.1%, 15.3%
8.7%, 11.0%
(1.6)%, (0.7)%
3.5%, 4.4%

-- 12 of 33 --

2021 2020 %
Increase
(Decrease)	Amount % to Sales Amount % to Sales
Sales to customers $24,804 100.0 $22,475 100.0 10.4
Cost of products sold 7,955 32.1 7,814 34.8 1.8
Gross Profit 16,849 67.9 14,661 65.2 14.9
Selling, marketing and administrative expenses 7,154 28.9 6,457 28.7 10.8
Research and development expense 4,720 19.0 4,032 17.9 17.1
In-process research and development 0 0.0 37 0.2
Interest (income) expense, net 47 0.2 74 0.3
Other (income) expense, net 9 0.0 2,354 10.5
Restructuring 83 0.3 60 0.3
Earnings before provision for taxes on income 4,836 19.5 1,647 7.3 193.6
Provision for/(Benefit from) taxes on income 100 0.4 (91) (0.4) (209.9)
Net Earnings $4,736 19.1 $1,738 7.7 172.5
-
Net earnings per share (Diluted) $1.77 $0.65 172.3
Average shares outstanding (Diluted) 2,670.2 2,669.2
Effective tax rate 2.1% (5.5)%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income $6,339 25.6 $5,601 24.9 13.2
Net earnings $5,678 22.9 $4,965 22.1 14.4
Net earnings per share (Diluted) $2.13 $1.86 14.5
Effective tax rate 10.4% 11.4%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 13
4th Quarter 2021
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 13 of 33 --

Adjusted Income Before Tax by Segment1
4th Quarter 2021
14
Pharmaceutical
Medical Devices
Consumer Health
Expenses Not Allocated to Segments
4Q 2021 4Q 2020
Pharmaceutical 34.0% 32.9%
Medical Devices 18.1% 16.5%
Consumer Health 17.9% 22.5%
Total 25.6% 24.9%
% to Sales
$5.3
$0.9
$5.7
$1.7 $1.3
2021 2020
($0.3)	($0.4)
$5.6B
$4.0
$0.8
$6.3B
$4.9
$1.2
$0.6
2
$1.1
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 1/25/2022

-- 14 of 33 --

2021 2020 %
Increase
(Decrease)	Amount % to Sales Amount % to Sales
Sales to customers $93,775 100.0 $82,584 100.0 13.6
Cost of products sold 29,855 31.8 28,427 34.4 5.0
Gross Profit 63,920 68.2 54,157 65.6 18.0
Selling, marketing and administrative expenses 24,659 26.3 22,084 26.8 11.7
Research and development expense 14,714 15.7 12,159 14.7 21.0
In-process research and development 900 1.0 181 0.2
Interest (income) expense, net 130 0.1 90 0.1
Other (income) expense, net 489 0.5 2,899 3.5
Restructuring 252 0.3 247 0.3
Earnings before provision for taxes on income 22,776 24.3 16,497 20.0 38.1
Provision for taxes on income 1,898 2.0 1,783 2.2 6.4
Net Earnings $20,878 22.3 $14,714 17.8 41.9
-
Net earnings per share (Diluted) $7.81 $5.51 41.7
Average shares outstanding (Diluted) 2,674.0 2,670.7
Effective tax rate 8.3% 10.8%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income $30,464 32.5 $25,428 30.8 19.8
Net earnings $26,195 27.9 $21,433 26.0 22.2
Net earnings per share (Diluted) $9.80 $8.03 22.0
Effective tax rate 14.0% 15.7%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 15
Full Year 2021
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 15 of 33 --

Adjusted Income Before Tax by Segment1
Full Year 2021
16
Pharmaceutical
Medical Devices
Consumer Health
Expenses Not Allocated to Segments
2021 2020
Pharmaceutical 40.5% 42.0%
Medical Devices 25.7% 17.0%
Consumer Health 23.8% 23.8%
Total 32.5% 30.8%
% to Sales
2021 2020
($1.1) ($0.9)
$25.4B
$19.1
$3.9
$3.3
$30.5B
$21.1
$7.0
$3.5
2
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 1/25/2022

-- 16 of 33 --

Notable New Announcements in 4th Quarter 20211
Pharmaceutical
• Regulatory Decisions:
– European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults
– U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
– Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® (amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations
After Failure of Platinum-Based Therapy
– Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
– World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
– Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
– FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
• Regulatory Submission:
– Janssen Seeks Approval of IMBRUVICA® (ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL) (EU)
– Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
• Other:
– Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
– Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World’s Most Vulnerable People through Novel Humanitarian Buffer
– Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Medical Devices
• Regulatory Decisions:
– U.S. FDA Approves New MENTOR® MemoryGel BOOST™ Breast Implant2
• Other:
– Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with Microsoft to Further Enable its Digital Surgery Solutions2
Enterprise
• Other
– Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business
– Johnson & Johnson Appoints Senior Leaders to Executive Committee
– Johnson & Johnson announces significant progress towards its climate goals – 100% renewable electricity for all sites in the United States, Canada and Europe by 2023
17
1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com
2 Subsequent to the quarter

-- 17 of 33 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 18 of 33 --

Creating Two
Global Leaders
That Will Advance
Our Mission
Pursue More Targeted
Business Strategies and
Accelerate Growth
Carry on Johnson & Johnson’s
Legacy of Putting the
People We Serve First
Deliver Improved Health
Outcomes for Patients
and Consumers
Create Opportunities for
Our Talented Global Team
We are taking a bold, Credo-based action to
evolve our business in order to provide
value to our stakeholders today, tomorrow,
and in the decades ahead
19

-- 19 of 33 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions Q4 2021
Cash and Marketable
Securities $32
Debt ($34)
Net Debt ($2)
Free Cash Flow1,2 ~$20
Full Year 2021:
$14.7B invested in R&D
$11.0B in dividends paid
to shareholders
Note: values may have been rounded
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of January 25, 2022. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 20

-- 20 of 33 --

21
2022 Sales Guidance
Consumer Health
• Expect some continued COVID-19
headwinds, but anticipate overall
market recovery to improve throughout
the year
• Assume continued competitive
momentum as year progresses with
value maximization of significant prior
year launches
Medical Devices
• Anticipate external supply constraints
to continue and estimate the majority
of impact will be in first half of 2022,
primarily the first quarter, in Skin
Health/Beauty
• Expect the second half of 2022 to
outperform the first half
Pharmaceutical
1 Non-GAAP measure; excludes acquisitions and divestitures 3 Euro Average Rate: January 2022 = $1.14
2 Non-GAAP measure; excludes the impact of translational currency Note: Percentages may be rounded
Phasing Considerations by Segment
• Anticipate another year of above-
market growth
• Relatively consistent growth across
all four quarters
January (Base Business) January (Incl. COVID-19
Vaccine) Comments
Adjusted Operational Sales1,2 6.5% - 7.5% 7.0% - 8.5%
Estimated COVID-19
Vaccine sales of
$3.0B - $3.5B
Operational Sales2 $97.3B - $98.3B
6.5% - 7.5%
$100.3B - $101.8B
7.0% – 8.5%
Estimated Reported Sales3 $95.9B - $96.9B
5.0% - 6.0%
$98.9B - $100.4B
5.5% – 7.0%

-- 21 of 33 --

2022 P&L Guidance
1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items Note: Percentages may be rounded
2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: January 2022 = $1.14 6 Comment updated 1-26-2022
January (Incl. COVID-19
Vaccine) Comments
Adjusted Operational Sales1,2 7.0% - 8.5% Midpoint of 7.7%
Operational Sales2 $100.3B - $101.8B
7.0% – 8.5%
Estimated COVID-19 Vaccine
sales of $3.0B - $3.5B
Estimated Reported Sales 3 $98.9B - $100.4B
5.5% – 7.0%
FX ($1.4B) or (1.5%) impact
Midpoint of $99.6B or 6.2%
Adjusted Pre-Tax
Operating Margin4,5 ~50 bps improvement OPEX leverage partially offset
by inflationary pressures in COGS
Net Other Income4 $1.2 - $1.4 billion Generally consistent with 2021 levels
Net Interest Expense / (Income) $0 - $100 million
Effective Tax Rate4 15.5% - 16.5% Geographic mix and the impact of
2022 OUS tax legislation changes6
Adjusted EPS (Operational)2,4 $10.60 - $10.80
8.2% - 10.2% Midpoint of $10.70 or 9.2%
Adjusted EPS (Reported)3,4 $10.40 - $10.60
6.1% - 8.2%
FX ($0.20) or (2.1%) impact
Midpoint of $10.50 or 7.1%
22

-- 22 of 33 --

Joaquin Duato
Chief Executive Officer
4TH QUARTER 2021
EARNINGS

-- 23 of 33 --

24

-- 24 of 33 --



-- 25 of 33 --



-- 26 of 33 --



-- 27 of 33 --



-- 28 of 33 --

Q&A
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Chief Executive Officer
Joaquin Duato

-- 29 of 33 --



-- 30 of 33 --

OTC
$5,227 Skin Health/Beauty
$4,541
Oral Care
$1,645
Baby Care
$1,566
Women's Health
$917
Wound Care/Other
$739
$14,635
4.1%, 2.8%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Consumer Health Highlights – Full Year 2021
Solid growth across all regions primarily driven by OTC
31
Key Drivers of Operational Performance1
OTC
• Growth driven by increased U.S. adult & pediatric fever and allergy incidences, Cough,
Cold, & Flu and Digestive Health category recovery, continued momentum in
NICORETTE, China MOTRIN recovery, ORSL HCP recommendations, and U.S. and
Korea Adult TYLENOL increased consumption for vaccination symptom relief
Skin
Health/
Beauty
• Growth driven by COVID-19 recovery, strong performance of NEUTROGENA and
AVEENO, and e-commerce acceleration partially offset by divestitures of DR. CI LABO
– Sedona and ROC
Oral Care
• Decline driven by floss divestiture and U.S. external supply constraints partially offset
by market growth in the U.S. along with strong performance in ASPAC due to
successful brand building and promotional campaigns
Baby Care • Growth driven by AVEENO ASPAC e-commerce strength, innovation and COVID-19
recovery, coupled with LATAM price actions and share gains
Women’s
Health
• Growth driven by COVID-19 recovery, price actions, and strong brand building in
ASPAC partially offset by flooding negatively impacting EMEA
Wound
Care/Other
• Growth driven by strong performance in BAND-AID® Brand Adhesive Bandages in the
U.S. partially offset by product discontinuations and competitive pressures in ASPAC
Adjusted Operational Sales2: WW 3.8%, U.S. 3.0%, Int’l 4.4%
Additional 2020 shipping days negatively impacted WW growth by ~1%
Reported: WW 4.1%, U.S. 2.4%, Int’l 5.6%
Operational1: WW 2.8%, U.S. 2.4%, Int’l 3.1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
8.4%, 6.2%
1.8%, 1.9%
2.6%, 1.2%
3.2%, 2.9%
0.2%, (1.2)%
2.0%, 1.0%

-- 31 of 33 --

Key Drivers of Operational Performance1
Immunology
• Growth driven by continued strong uptake of STELARA in Crohn’s Disease and
Ulcerative Colitis, strength of TREMFYA in Psoriasis and uptake in Psoriatic Arthritis
• REMICADE decline due to biosimilar competition
Infectious
Diseases
• Growth driven by the contribution of the COVID-19 vaccine
• Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA
and PREZISTA OUS LOE
Neuroscience
• Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts
and persistency, and the launch of INVEGA HAFYERA
Oncology
• DARZALEX increase driven by continued strong market growth and share gains in
all regions and solid uptake of the subcutaneous formulation launched in 2020
• IMBRUVICA growth primarily driven by market and continued share leadership,
partially offset by COVID-19 related market dynamics including continued delays in
new patient starts as well as competitive pressures
• Continued strong global launch uptake of ERLEADA
Cardiovascular/
Metabolism/
Other
(CVM/Other)
• Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition
• INVOKANA/INVOKAMET decline due to continued share erosion
Pulmonary
Hypertension
(PH)
• Growth driven by strong sales of OPSUMIT and UPTRAVI due to continued share
gains and market growth
Adjusted Operational Sales2: WW 13.6%, U.S. 8.6%, Int’l 20.2%
Additional 2020 shipping days negatively impacted WW growth by ~1%Immunology
$16,750
Infectious Diseases
$5,861
Neuroscience
$7,011
Oncology
$14,548
CVM/Other
$4,460
PH
$3,450
$52,080
14.3%, 13.1%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Pharmaceutical Highlights – Full Year 2021
32
Reported: WW 14.3%, U.S. 8.6%, Int’l 21.6%
Operational1: WW 13.1%, U.S. 8.6%, Int’l 18.8%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
(8.6)%, (9.6)%
9.6%, 9.2%
17.6%, 16.0%
7.1%, 5.9%
64.0%, 62.5%
11.3%, 10.2%
10th consecutive year of above-market performance driven by double-digit growth in key products

-- 32 of 33 --

Orthopaedics
$8,588
Surgery
$9,812
Vision
$4,688
Interventional
Solutions
$3,971
$27,060
17.9%, 16.2%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Medical Devices Highlights – Full Year 2021
Growth primarily driven by COVID-19 related market recovery, commercial initiatives and innovation
33
Reported: WW 17.9%, U.S. 14.9%, Int’l 20.6%
Operational1: WW 16.2%, U.S. 14.9%, Int’l 17.3%
Key Drivers of Operational Performance1
Interventional
Solutions
• Market recovery, success of new products (VIZIGO and CARTO V7) and commercial
strategies continuing to enhance global leadership
Orthopaedics
• Hips: Growth reflects market recovery combined with continued strength of our portfolio
including the ACTIS stem and enabling technologies – KINCISE & VELYS Hip Navigation
• Trauma: Growth reflects global market recovery and uptake of new products including
Cannulated Compression Headless Screws, Advanced Nailing Systems and FIBULINK
• Knees: Growth primarily driven by procedure recovery and new product introductions
• Spine, Sports & Other: Growth driven primarily by COVID-19 market recovery and new
products in Spine and Sports
• Spine: WW: ~+4%, U.S.: ~+3%, OUS: ~+5%
Surgery
• Advanced:
• Endocutters: ~+16% Driven by market recovery and new products (ECHELON Staple
Line Reinforcement) offsetting competitive pressure in the U.S.
• Biosurgery: ~+19% Market recovery and share expansion driven by success of newer
products (VISTASEAL and SURGICEL POWDER) and ASPAC market expansion
• Energy: ~+18% Primarily due to market recovery, new products and market expansion
offsetting competitive pressures in the U.S.
• General: Growth primarily driven by market recovery and continued strength of the Suture
portfolio
Vision
• Contact Lenses/Other: Growth driven primarily by market recovery and market share
gains from new products (ACUVUE OASYS Multifocal and ACUVUE DEFINE Fresh).
• Surgical: Growth primarily due to market recovery and market share gains from uptake of
recently launched products (TECNIS EYHANCE and TECNIS SYNERGY)
Adjusted Operational Sales2: WW 16.8%, U.S. 15.3%, Int’l 18.3%
Additional 2020 shipping days negatively impacted WW growth by ~1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding; Beginning in the fiscal first quarter of 2022, the Medical Devices segment will be referred to as the MedTech segment
30.4%, 28.2%
19.6%, 19.0%
10.6%, 9.1%
19.2%, 17.0%

-- 33 of 33 --